Background
==========

Breast cancer is a worldwide problem, and is the leading cause of cancer morbidity and mortality in females \[[@b1-medscimonit-26-e924858]\]. The long-term survival of breast cancer patients has been investigated, and the global 5- and 10-year pooled survival rates were reported to be 73% (95% CI: 71--75%) and 61% (95% CI: 54--67%), respectively \[[@b2-medscimonit-26-e924858]\].

Early death is a crucial issue in the management of cancer. A series of studies have been conducted to investigate early death in cancer, including lung cancer \[[@b3-medscimonit-26-e924858]\], bladder cancer \[[@b4-medscimonit-26-e924858]\], and colorectal cancer \[[@b5-medscimonit-26-e924858]\]. The related factors for early death revealed in these studies provided evidence for cancer treatment. For primary breast cancer, around 10% of the patients died during the first year after initial diagnosis. Age over 80 years and distant metastases at presentation were proved to be the risk factors leading to early death. Meanwhile, surgery was reported to be able to decrease the risk of early death (OR=0.29, 95% CI: 0.24--0.35) \[[@b6-medscimonit-26-e924858]\].

As to the United States, approximately 5% of women with newly diagnosed breast cancer were reported to present with stage IV at diagnosis \[[@b7-medscimonit-26-e924858]\]. The proportion of stage IV breast cancer was even higher in the Asian population \[[@b8-medscimonit-26-e924858]\]. Compared with patients in early stage, patients in advanced stage were reported to have worse survival. The reported unadjusted median overall survival was 3.52 years in patients after surgery and 2.36 years in those without surgery \[[@b9-medscimonit-26-e924858]\].

The identification of factors correlated with early death in stage IV breast cancer is important. Based on a large cohort, we sought to identify the patients who died within 12 months after stage IV breast cancer diagnosis and to investigate the risk factors. Furthermore, predictive nomograms based on the results from the logistic regression model were constructed to predict the early death in stage IV breast cancer and to guide personalized early death risk screening.

Material and Methods
====================

Data source and cohort selection
--------------------------------

The National Cancer Institute Surveillance, Epidemiology and End Results (SEER) database (*<https://seer.cancer.gov/>*) covers approximately 28% of the population in the USA. The data used in the present study were obtained from the latest version by April 2019, which was named as Incidence -- SEER 18 Regs Research Data+Hurricane Katrina Impacted Louisiana Cases, Nov 2018 Sub (1975--2016 varying).

Breast cancer patients at stage IV diagnosed between 2010 and 2015 were included into the construction cohort. In order to validate performance of the prediction model, temporal validation was conducted as internal validation. In the validation cohort, breast cancer patients at stage IV diagnosed in 2016 were used to validate the performance. The exclusion criteria were as follows: patients diagnosed at autopsy or via death certificate, male patients, and those without detailed information about site-specific metastases. The flow-chart of subject selection is listed in [Figure 1](#f1-medscimonit-26-e924858){ref-type="fig"}. As in a previous study, early death in breast cancer patients was defined as death within 1 year after initial diagnosis \[[@b6-medscimonit-26-e924858]\].

Statistical analysis
--------------------

The variables of the extracted data from the SEER database included age at diagnosis (\<50, 50--59, 60--69, 70--79, and ≥80 years), marital status (married and unmarried), race (white, black and others), insurance recode (insured and uninsured), breast cancer subtypes (Luminal A, Luminal B, HER2 enriched, and triple-negative), tumor grade (I to IV: well, moderately, poorly, and undifferentiated, respectively), primary tumor site (C50.4-outer quadrant, UOQ; C50.5-lower outer quadrant, LOQ; C50.3-lower inner quadrant, LIQ; C50.2-upper inner quadrant, UIQ; C50.1-central portion, CEN; others including C50.0-Nipple, C50.6-Axillary tail of breast and C50.8-Overlapping lesion of breast), laterality (left-sided, right-sided, one side, NOS and paired sides), tumor size (0--2, 2--5 and \>5 cm), N stage (N0, N1, N2 and N3), bone metastasis (no or yes), brain metastasis (no or yes), liver metastasis (no or yes), lung metastasis (no or yes), surgery treatment (no surgery; partial mastectomy, PM; total mastectomy, TM; radical mastectomy, RM; and others, including local tumor destruction, subcutaneous mastectomy, and bilateral mastectomy).

All of the variables in our study were categorical data, which are presented as numbers and percentages. A logistics regression model was used to identify the risk factors for early death. Variables with P\<0.05 in the univariate analysis were further used in the multivariate analysis to determine the potential risk factors. The cases with missing data were excluded from the logistics analysis. Based on the results from the logistic regression model, the nomograms for all-cause, cancer-specific, and non-cancer-specific early death were formulated using the rms package in R version 3.4.1 (R Foundation for Statistical Computing, Vienna, Austria; [www.r-project.org](www.r-project.org)). The calibration plots produced by bootstrapping with 1000 resamples were used to test the calibration of the nomograms. The discrimination of the nomograms was evaluated by the receiver operating characteristics (ROC). A greater area under the curve (AUC) close to 1.0 indicated better ability of discrimination.

Data extraction was performed using the SEER\*Stat Software and statistical analyses were performed using SPSS 23.0 (IBM Corporation, Armonk, NY, USA). All statistical tests were two-sided, and P\<0.05 was considered significant.

Ethics statement
----------------

The SEER dataset is a freely available database, and the data released by SEER do not require informed patient consent because cancer is a reportable disease in every state in the USA. The present study complied with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.

Results
=======

Clinical characteristics and incidence of early death
-----------------------------------------------------

After excluding patients diagnosed by autopsy or death certificate, male patients, and those without complete records, a total of 18 406 breast cancer patients at stage IV were enrolled in the construction cohort. Patients' basic characteristics are summarized in [Table 1](#t1-medscimonit-26-e924858){ref-type="table"}. According to the pre-definition, 5998 (32.6%) patients were categorized as early death, among whom 4416 patients died due to cancer-specific cause. Most patients with early death were diagnosed after age 50 years (89.2%). The most common cancer subtype was Luminal A (38.3%), followed by triple-negative (19.4%), Luminal B, and HER2 enriched type. Except for the unknown grade, grade III (37.0%) and II (23.9%) were the most common types. Distant metastasis was found in 3842 (64.1%) patients in bone, 2471 (41.2%) patients in lung, 2178 (36.3%) patients in liver, and 820 (13.7%) patients in brain. A total of 5094 (84.9%) patients did not receive any surgical intervention.

Risk factors for early death
----------------------------

In the univariate logistic regression, diagnosis age older than 50 years, unmarried status, black race, uninsured status, HER2-enriched and triple-negative types, grade (II--IV), tumor size \>5 cm, paired sides, and distant metastases (lung, liver and brain) were associated with greater risk of total early death. Other race, Luminal B subtype, N1 and N2 stage, and surgical interventions significantly decreased the risk of early death. As for cause of death, uninsured status, Luminal B subtype, tumor size 2--5 cm and \>5 cm, and N3 stage showed different trends in the cancer-specific and non-cancer-specific early death. [Table 2](#t2-medscimonit-26-e924858){ref-type="table"} provides detailed information.

When adjusting these factors in the multivariate logistic regression, the independent risk factors for total early death included age older than 50 years, unmarried status, black race, uninsured status, triple-negative type, grade (II and III), tumor size \>5 cm, and metastasis to lung, liver, and brain. Luminal B subtype, N1 stage, and surgical interventions were significantly associated with lower risk of early death. Unmarried status, uninsured status, Luminal B subtype, grade (II and III), tumor size 2--5 cm and \>5 cm, N1 stage, and metastasis to bone and lung were not consistent between the cancer-specific and non-cancer-specific early death groups. [Table 3](#t3-medscimonit-26-e924858){ref-type="table"} provides detailed information.

Performance of the nomograms for predicting early death
-------------------------------------------------------

Nomograms predicting the risk of early death are shown in [Figure 2](#f2-medscimonit-26-e924858){ref-type="fig"} ([Figure 2A--2C](#f2-medscimonit-26-e924858){ref-type="fig"} for all-cause, cancer-specific, and non-cancer-specific early death, respectively). Excellent ability of calibration was achieved in the 3 predictive models, with all calibration curve close to the 45-degree line ([Figure 3A--3C](#f3-medscimonit-26-e924858){ref-type="fig"} for all-cause, cancer-specific, and non-cancer-specific early death, respectively). All 3 nomograms showed satisfactory strength of discrimination ([Figure 3D--3F](#f3-medscimonit-26-e924858){ref-type="fig"}). The AUC for nomograms of the all-cause, cancer-specific, and non-cancer-specific early death prediction were 78.3% (95% CI: 77.7--78.9%), 75.8% (95% CI: 75.1--76.4%), and 72.3% (95% CI: 71.6--72.9%), respectively.

In the validation cohort, a total of 689 (19.3%) breast cancer patients were diagnosed as early death, among whom 508 patients died due to cancer-specific causes. Patients' basic characteristics are shown in [Supplementary Table 1](#s1-medscimonit-26-e924858){ref-type="supplementary-material"}. The calibration curve showed satisfactory agreement ([Supplementary Figure 1A--1C](#s2-medscimonit-26-e924858){ref-type="supplementary-material"}). As shown in [Supplementary Figure 1D--1F](#s2-medscimonit-26-e924858){ref-type="supplementary-material"}, the AUC for nomograms of the all-cause, cancer-specific, and non-cancer-specific early death prediction were 74.0% (95% CI: 72.5--75.4%), 73.5% (72.0--74.9%), and 68.6% (67.0--70.1%), respectively.

Discussion
==========

The present study in a large cohort is the first to prove that the survival of one-third of the stage IV breast cancer patients was less than 12 months. Compared with the previously reported proportion of early death by the national cancer database (19.4%), the proportion in the present study is higher \[[@b10-medscimonit-26-e924858]\]. Cardiovascular disease and breast cancer were previously reported to be the primary causes of mortality in breast cancer survivors \[[@b11-medscimonit-26-e924858]\]. In the present study, the cancer-specific cause was proved to be the most important reason, resulting in 73.6% of all the early deaths in the patients with stage IV breast cancer. Efforts to reduce the risk of cancer-specific early death are crucial to improving the total survival.

Several risk factors were identified in the present study for patients with early death. Age was found to be a common risk factor for early death, and most of the early death cases were patients older than 50 years. The proportion of early death due to the 2 causes showed disparities in age at diagnosis, with a trend of more non-cancer-specific early death in older patients, which is consistent with a previous study \[[@b12-medscimonit-26-e924858]\]. Therefore, health care should be provided to meet the needs of patients in specific age groups.

Since the pioneering work by Perou et al. \[[@b13-medscimonit-26-e924858]\] and Sorlie et al. \[[@b14-medscimonit-26-e924858]\], breast cancer has been divided into different subtypes, and enormous studies have been conducted to investigate the relationship between survival and each subtype. In the present study, different subtypes were associated with various odds of early death. Compared with the Luminal A breast cancer, the triple-negative type was a risk factor resulting in more cancer-specific and non-cancer-specific early death. Luminal B was a protective factor for cancer-specific early death. The trend was also reported in the latest study \[[@b15-medscimonit-26-e924858]\]. Therefore, clear pathological diagnosis is important to predict early death and more studies should be performed among patients with triple-negative breast cancer.

Distant metastasis was the main characteristic of stage IV breast cancer. Bone was the most common metastatic site in our study, followed by lung, liver, and brain. Multivariate analysis showed that metastasis to liver and brain was a common risk factor for cancer-specific and non-cancer-specific early death, while metastases to bone and lung were associated with higher odds of cancer-specific early death. Due to the fact that bone and lung accounted for three-quarters of all metastases, more screenings should be scheduled to test these organs.

Socioeconomic variables were significantly associated with cancer management \[[@b16-medscimonit-26-e924858]\]. Because unmarried and uninsured patients are less likely to receive adequate mental and financial support, such patients have limited resources for their cancer treatment. Compared with white patients, black patients also had higher risk for early death. Previous studies have investigated the racial differences in breast cancer molecular features, and indicated black patients were more likely to have basal-like and HER2-enriched breast cancer subtypes \[[@b17-medscimonit-26-e924858]\]. Another study reported that black women were significantly more likely to develop triple-negative breast cancer \[[@b18-medscimonit-26-e924858]\]. In addition to the biological disadvantage, neoadjuvant chemotherapy was less likely to be completed in non-white patients, after controlling other factors \[[@b19-medscimonit-26-e924858]\]. The underlying reasons should be investigated in further studies.

Among the investigated variables in this study, surgery was the most important protective factor for lower odds of early death. Partial, total, and radical mastectomy can significantly decrease the risk of early death. Surgery resulting in improved survival of breast cancer with distant metastasis has been reported in several studies \[[@b20-medscimonit-26-e924858],[@b21-medscimonit-26-e924858]\]. However, only less than 15% of all stage IV patients received surgery in this cohort from the SEER database. As with all retrospective reviews, there was a possible patient selection bias contributing to the better results in the patients after surgery \[[@b9-medscimonit-26-e924858]\]. Patients with better conditions and less risk were reported to be more likely to receive surgical interventions \[[@b7-medscimonit-26-e924858]\]. Therefore, the actual benefit from surgery for stage IV breast cancer should be evaluated.

In the current clinical processing, it was not convenient to predict the possibility of early death for individual patients. Several risk factors for early death were revealed in the present study. Based on the revealed factors, the nomograms were constructed, and this predictive system can be an effective method for use in clinical practice \[[@b5-medscimonit-26-e924858]\].

Our study had several limitations. First, we defined the early death as those who died within 1 year after diagnosis. With larger populations, other intervals such as 3 and 6 months should be further investigated. Second, the SEER database only recorded the synchronous metastasis in breast cancer, and data on patients with metachronous metastasis were not available. Third, breast cancer has distinct heterogeneity, and patients with different subtypes should receive different individual treatment modalities. However, detailed information on targeted treatment and specific regimens of adjuvant chemotherapy were not available in the SEER database.

Conclusions
===========

Early death occurs in one-third of stage IV breast cancer patients, and the cancer-specific death was the most common cause. A series of risk factors for early death were identified. Based on these factors, nomograms for predicting early death were constructed. This predictive system can guide and schedule targeted treatment regimens for patients with stage IV breast cancer.

Supplementary Data
==================

###### 

Description of the early death for patients with IV breast cancer in the validation cohort.

  Subject characteristics   Patients No. (%)                             
  ------------------------- ------------------ ------------ ------------ ------------
  Age                                                                    
   \<50                     600 (20.8)         64 (9.3)     51 (10.0)    13 (7.2)
   50--59                   655 (22.7)         131 (19)     101 (19.9)   30 (16.6)
   60--69                   771 (26.7)         178 (25.8)   136 (26.8)   42 (23.2)
   70--79                   527 (18.2)         133 (19.3)   97 (19.1)    36 (19.9)
   ≥80                      337 (11.7)         183 (26.6)   123 (24.2)   60 (33.1)
  Marital status                                                         
   Married                  1341 (46.4)        213 (30.9)   164 (32.3)   49 (27.1)
   Unmarried                1390 (48.1)        441 (64)     321 (63.2)   120 (66.3)
   Unknown                  159 (5.5)          35 (5.1)     23 (4.5)     12 (6.6)
  Race                                                                   
   White                    2206 (76.3)        498 (72.3)   369 (72.6)   129 (71.3)
   Black                    402 (13.9)         147 (21.3)   109 (21.5)   38 (21)
   Others                   260 (9.0)          41 (6.0)     27 (5.3)     14 (7.7)
   Unknown                  22 (0.8)           3 (0.4)      3 (0.6)      0 (0)
  Insurance                                                              
   Insured                  2737 (94.7)        640 (92.9)   466 (91.7)   174 (96.1)
   Uninsured                75 (2.6)           31 (4.5)     27 (5.3)     4 (2.2)
   Unknown                  78 (2.7)           18 (2.6)     15 (3.0)     3 (1.7)
  Subtypes                                                               
   Luminal A                1612 (55.8)        239 (34.7)   174 (34.3)   65 (35.9)
   Luminal B                476 (16.5)         76 (11.0)    58 (11.4)    18 (9.9)
   HER2 enriched            222 (7.7)          55 (8.0)     42 (8.3)     13 (7.2)
   Triple negative          295 (10.2)         110 (16.0)   76 (15.0)    34 (18.8)
   Unknown                  285 (9.9)          209 (30.3)   158 (31.1)   51 (28.2)
  Grade                                                                  
   Grade I                  204 (7.1)          27 (3.9)     22 (4.3)     5 (2.8)
   Grade II                 1065 (36.9)        139 (20.2)   98 (19.3)    41 (22.7)
   Grade III                1006 (34.8)        233 (33.8)   172 (33.9)   61 (33.7)
   Grade IV                 5 (0.2)            3 (0.4)      2 (0.4)      1 (0.6)
   Unknown                  610 (21.1)         287 (41.7)   214 (42.1)   73 (40.3)
  Tumor site                                                             
   UOQ                      764 (26.4)         128 (18.6)   93 (18.3)    35 (19.3)
   LOQ                      162 (5.6)          19 (2.8)     12 (2.4)     7 (3.9)
   LIQ                      98 (3.4)           20 (2.9)     12 (2.4)     8 (4.4)
   UIQ                      161 (5.6)          32 (4.6)     24 (4.7)     8 (4.4)
   CEN                      188 (6.5)          32 (4.6)     26 (5.1)     6 (3.3)
   Others                   577 (20.0)         116 (16.8)   86 (16.9)    30 (16.6)
   Unknown                  940 (32.5)         342 (49.6)   255 (50.2)   87 (48.1)
  Laterality                                                             
   Left-sided               1371 (47.4)        312 (45.3)   233 (45.9)   79 (43.6)
   Right-sided              1387 (48.0)        310 (45.0)   226 (44.5)   84 (46.4)
   One side, NOS            10 (0.3)           3 (0.4)      2 (0.4)      1 (0.6)
   Paired sides             122 (4.2)          64 (9.3)     47 (9.3)     17 (9.4)
  Tumor size                                                             
   0--2 cm                  414 (14.3)         86 (12.5)    63 (12.4)    23 (12.7)
   2--5 cm                  1076 (37.2)        196 (28.4)   138 (27.2)   58 (32.0)
   \>5 cm                   794 (27.5)         177 (25.7)   138 (27.2)   39 (21.5)
   Unknown                  606 (21.0)         230 (33.4)   169 (33.3)   61 (33.7)
  N stage                                                                
   N0                       664 (23)           196 (28.4)   142 (28.0)   54 (29.8)
   N1                       1200 (41.5)        243 (35.3)   180 (35.4)   63 (34.8)
   N2                       329 (11.4)         53 (7.7)     40 (7.9)     13 (7.2)
   N3                       430 (14.9)         74 (10.7)    60 (11.8)    14 (7.7)
   Unknown                  267 (9.2)          123 (17.9)   86 (16.9)    37 (20.4)
  Bone Met                                                               
   No                       1014 (35.1)        254 (36.9)   166 (32.7)   88 (48.6)
   Yes                      1876 (64.9)        435 (63.1)   342 (67.3)   93 (51.4)
  Brain Met                                                              
   No                       2747 (95.1)        612 (88.8)   448 (88.2)   164 (90.6)
   Yes                      143 (4.9)          77 (11.2)    60 (11.8)    17 (9.4)
  Liver Met                                                              
   No                       2289 (79.2)        411 (59.7)   282 (55.5)   129 (71.3)
   Yes                      601 (20.8)         278 (40.3)   226 (44.5)   52 (28.7)
  Lung Met                                                               
   No                       2055 (71.1)        423 (61.4)   306 (60.2)   117 (64.6)
   Yes                      835 (28.9)         266 (38.6)   202 (39.8)   64 (35.4)
  Surgery                                                                
   No Surgery               2127 (73.6)        633 (91.9)   467 (91.9)   166 (91.7)
   PM                       220 (7.6)          18 (2.6)     13 (2.6)     5 (2.8)
   TM                       240 (8.3)          17 (2.5)     13 (2.6)     4 (2.2)
   RM                       263 (9.1)          16 (2.3)     12 (2.4)     4 (2.2)
   Others                   14 (0.5)           0 (0)        0 (0)        0 (0)
   Unknown                  26 (0.9)           5 (0.7)      3 (0.6)      2 (1.1)

UOQ -- upper outer quadrant; LOQ -- lower outer quadrant; LIQ -- lower inner quadrant; UIQ -- upper inner quadrant; CEN -- central portion; NOS -- not otherwise specified; PM -- partial mastectomy; TM -- total mastectomy; RM -- radical mastectomy.

###### 

The calibration curve and ROC curve for assessing the calibration and discrimination of the nomograms in predicting all-cause early death (**A, D**), cancer-specific early death (**B, E**) and non-cancer-specific early death (**C, F**) in the validation cohort.
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###### 

Description of the early death for patients with IV breast cancer in the construction cohort.

  Subject characteristics   Patients No. (%)                               
  ------------------------- ------------------ ------------- ------------- -------------
  Age                                                                      
   \<50                     2790 (22.5)        645 (10.8)    521 (11.8)    124 (7.8)
   50--59                   3256 (26.2)        1178 (19.6)   923 (20.9)    255 (16.1)
   60--69                   3267 (26.3)        1506 (25.1)   1128 (25.5)   378 (23.9)
   70--79                   1952 (15.7)        1318 (22.0)   940 (21.3)    378 (23.9)
   ≥80                      1143 (9.2)         1351 (22.5)   904 (20.5)    447 (28.3)
  Marital status                                                           
   Married                  5790 (46.7)        1993 (33.2)   1477 (33.4)   516 (32.6)
   Unmarried                5922 (47.7)        3674 (61.3)   2697 (61.1)   977 (61.8)
   Unknown                  696 (5.6)          331 (5.5)     242 (5.5)     89 (5.6)
  Race                                                                     
   White                    9466 (76.3)        4409 (73.5)   3252 (73.6)   1157 (73.1)
   Black                    1906 (15.4)        1208 (20.1)   881 (20)      327 (20.7)
   Others                   987 (8.0)          369 (6.2)     274 (6.2)     95 (6.0)
   Unknown                  49 (0.4)           12 (0.2)      9 (0.2)       3 (0.2)
  Insurance                                                                
   Insured                  11727 (94.5)       5527 (92.1)   4033 (91.3)   1494 (94.4)
   Uninsured                437 (3.5)          308 (5.1)     265 (6.0)     43 (2.7)
   Unknown                  244 (2.0)          163 (2.7)     118 (2.7)     45 (2.8)
  Subtypes                                                                 
   Luminal A                7274 (58.6)        2295 (38.3)   1645 (37.3)   650 (41.1)
   Luminal B                1961 (15.8)        544 (9.1)     427 (9.7)     117 (7.4)
   HER2 enriched            891 (7.2)          424 (7.1)     323 (7.3)     101 (6.4)
  Triple negative           908 (7.3)          1164 (19.4)   871 (19.7)    293 (18.5)
   Unknown                  1374 (11.1)        1571 (26.2)   1150 (26)     421 (26.6)
  Grade                                                                    
   Grade I                  979 (7.9)          212 (3.5)     140 (3.2)     72 (4.6)
   Grade II                 4401 (35.5)        1432 (23.9)   1021 (23.1)   411 (26)
   Grade III                4220 (34.0)        2220 (37.0)   1689 (38.2)   531 (33.6)
   Grade IV                 56 (0.5)           45 (0.8)      37 (0.8)      8 (0.5)
   Unknown                  2752 (22.2)        2089 (34.8)   1529 (34.6)   560 (35.4)
  Tumor site                                                               
   UOQ                      2930 (23.6)        1141 (19)     832 (18.8)    309 (19.5)
   LOQ                      684 (5.5)          226 (3.8)     162 (3.7)     64 (4.0)
   LIQ                      453 (3.7)          154 (2.6)     104 (2.4)     50 (3.2)
   UIQ                      794 (6.4)          284 (4.7)     204 (4.6)     80 (5.1)
   CEN                      761 (6.1)          288 (4.8)     212 (4.8)     76 (4.8)
   Others                   2577 (20.8)        1059 (17.7)   767 (17.4)    292 (18.5)
   Unknown                  4209 (33.9)        2846 (47.4)   2135 (48.3)   711 (44.9)
  Laterality                                                               
   Left-sided               6030 (48.6)        2848 (47.5)   2110 (47.8)   738 (46.6)
   Right-sided              5799 (46.7)        2684 (44.7)   1972 (44.7)   712 (45.0)
   One side, NOS            51 (0.4)           35 (0.6)      29 (0.7)      6 (0.4)
   Paired sides             528 (4.3)          431 (7.2)     305 (6.9)     126 (8.0)
  Tumor size                                                               
   0--2 cm                  1937 (15.6)        705 (11.8)    438 (9.9)     267 (16.9)
   2--5 cm                  4721 (38.0)        1871 (31.2)   1346 (30.5)   525 (33.2)
   \>5 cm                   3263 (26.3)        1580 (26.3)   1274 (28.8)   306 (19.3)
   Unknown                  2487 (20.0)        1842 (30.7)   1358 (30.8)   484 (30.6)
  N stage                                                                  
   N0                       2860 (23.0)        1490 (24.8)   991 (22.4)    499 (31.5)
   N1                       4321 (34.8)        1634 (27.2)   1266 (28.7)   368 (23.3)
   N2                       1131 (9.1)         370 (6.2)     276 (6.3)     94 (5.9)
   N3                       3092 (24.9)        1613 (26.9)   1237 (28)     376 (23.8)
   Unknown                  1004 (8.1)         891 (14.9)    646 (14.6)    245 (15.5)
  Bone Met                                                                 
   No                       3562 (28.7)        2156 (35.9)   1525 (34.5)   631 (39.9)
   Yes                      8846 (71.3)        3842 (64.1)   2891 (65.5)   951 (60.1)
  Brain Met                                                                
   No                       11786 (95.0)       5178 (86.3)   3792 (85.9)   1386 (87.6)
   Yes                      622 (5.0)          820 (13.7)    624 (14.1)    196 (12.4)
  Liver Met                                                                
   No                       9722 (78.4)        3820 (63.7)   2712 (61.4)   1108 (70)
   Yes                      2686 (21.6)        2178 (36.3)   1704 (38.6)   474 (30)
  Lung Met                                                                 
   No                       8861 (71.4)        3527 (58.8)   2521 (57.1)   1006 (63.6)
   Yes                      3547 (28.6)        2471 (41.2)   1895 (42.9)   576 (36.4)
  Surgery                                                                  
   No surgery               8177 (65.9)        5094 (84.9)   3785 (85.7)   1309 (82.7)
   PM                       1174 (9.5)         298 (5.0)     195 (4.4)     103 (6.5)
   TM                       984 (7.9)          201 (3.4)     132 (3)       69 (4.4)
   RM                       1851 (14.9)        339 (5.7)     251 (5.7)     88 (5.6)
   Others                   38 (0.3)           9 (0.2)       5 (0.1)       4 (0.3)
   Unknown                  184 (1.5)          57 (1.0)      48 (1.1)      9 (0.6)

UOQ -- upper outer quadrant; LOQ -- lower outer quadrant; LIQ -- lower inner quadrant; UIQ -- upper inner quadrant; CEN -- central portion; NOS -- not otherwise specified; PM -- partial mastectomy; TM -- total mastectomy; RM -- radical mastectomy.

###### 

Univariate logistic regression for analyzing the risk factors for early death in patients with IV breast cancer.

  Subject characteristics   Total early death   Cancer specific early death   Non-cancer specific early death                                 
  ------------------------- ------------------- ----------------------------- --------------------------------- --------- ------------------- ---------
  Age                                                                                                                                         
   \<50                     Ref                 1.0                           Ref                               1.0       Ref                 1.0
   50--59                   1.57 (1.40--1.74)   \<0.001                       1.47 (1.31--1.66)                 \<0.001   1.63 (1.31--2.03)   \<0.001
   60--69                   1.99 (1.80--2.22)   \<0.001                       1.73 (1.54--1.94)                 \<0.001   2.30 (1.87--2.83)   \<0.001
   70--79                   2.92 (2.62--3.26)   \<0.001                       2.26 (2.00--2.54)                 \<0.001   3.49 (2.83--4.30)   \<0.001
   ≥80                      5.11 (4.55--5.74)   \<0.001                       3.18 (2.81--3.60)                 \<0.001   5.83 (4.74--7.17)   \<0.001
  Marital status                                                                                                                              
   Married                  Ref                 1.0                           Ref                               1.0       Ref                 1.0
   Unmarried                1.80 (1.69--1.92)   \<0.001                       1.67 (1.55--1.79)                 \<0.001   1.60 (1.43--1.78)   \<0.001
  Race                                                                                                                                        
   White                    Ref                 1.0                           Ref                               1.0       Ref                 1.0
   Black                    1.36 (1.26--1.48)   \<0.001                       1.29 (1.18--1.41)                 \<0.001   1.29 (1.13--1.47)   \<0.001
   Others                   0.80 (0.71--0.91)   0.001                         0.83 (0.72--0.95)                 0.007     0.83 (0.67--1.03)   0.089
  Insurance                                                                                                                                   
   Insured                  Ref                 1.0                           Ref                               1.0       Ref                 1.0
   Uninsured                1.50 (1.29--1.74)   \<0.001                       1.81 (1.55--2.11)                 \<0.001   0.65 (0.47--0.88)   0.006
  Subtypes                                                                                                                                    
   Luminal A                Ref                 1.0                           Ref                               1.0       Ref                 1.0
   Luminal B                0.88 (0.79--0.98)   0.017                         0.99 (0.88--1.11)                 0.864     0.67 (0.55--0.82)   \<0.001
   HER2 enriched            1.51 (1.33--1.71)   \<0.001                       1.57 (1.37--1.80)                 \<0.001   1.14 (0.92--1.42)   0.234
   Triple negative          4.06 (3.68--4.48)   \<0.001                       3.49 (3.15--3.87)                 \<0.001   2.26 (1.95--2.62)   \<0.001
  Grade                                                                                                                                       
   Grade I                  Ref                 1.0                           Ref                               1.0       Ref                 1.0
   Grade II                 1.50 (1.28--1.76)   \<0.001                       1.59 (1.32--1.92)                 \<0.001   1.18 (0.91--1.53)   0.214
   Grade III                2.43 (2.08--2.84)   \<0.001                       2.67 (2.22--3.21)                 \<0.001   1.40 (1.08--1.80)   0.010
   Grade IV                 3.71 (2.44--5.65)   \<0.001                       4.34 (2.79--6.75)                 \<0.001   1.34 (0.63--2.86)   0.454
  Tumor site                                                                                                                                  
   UOQ                      Ref                 1.0                           Ref                               1.0       Ref                 1.0
   LOQ                      0.85 (0.72--1.00)   0.051                         0.84 (0.70--1.02)                 0.072     0.92 (0.70--1.22)   0.564
   LIQ                      0.87 (0.72--1.06)   0.173                         0.81 (0.64--1.01)                 0.058     1.09 (0.80--1.49)   0.577
   UIQ                      0.92 (0.79--1.07)   0.272                         0.91 (0.77--1.08)                 0.271     0.98 (0.76--1.26)   0.852
   CEN                      0.97 (0.84--1.13)   0.712                         0.99 (0.83--1.17)                 0.870     0.95 (0.73--1.23)   0.705
   Others                   1.06 (0.96--1.17)   0.287                         1.04 (0.93--1.16)                 0.477     1.06 (0.90--1.26)   0.472
  Laterality                                                                                                                                  
   Left-sided               Ref                 1.0                           Ref                               1.0       Ref                 1.0
   Right-sided              0.98 (0.92--1.05)   0.534                         0.97 (0.91--1.04)                 0.419     1.01 (0.91--1.13)   0.848
   One side, NOS            1.45 (0.94--2.24)   0.090                         1.63 (1.04--2.56)                 0.033     0.83 (0.36--1.90)   0.655
   Paired sides             1.73 (1.51--1.98)   \<0.001                       1.50 (1.30--1.73)                 \<0.001   1.67 (1.36--2.04)   \<0.001
  Tumor size                                                                                                                                  
   0--2 cm                  Ref                 1.0                           Ref                               1.0       Ref                 1.0
   2--5 cm                  1.09 (0.98--1.21)   0.100                         1.29 (1.15--1.45)                 \<0.001   0.77 (0.66--0.90)   0.001
   \>5 cm                   1.33 (1.20--1.48)   \<0.001                       1.80 (1.59--2.03)                 \<0.001   0.60 (0.51--0.71)   \<0.001
  N stage                                                                                                                                     
   N0                       Ref                 1.0                           Ref                               1.0       Ref                 1.0
   N1                       0.73 (0.67--0.79)   \<0.001                       0.92 (0.83--1.01)                 0.065     0.51 (0.44--0.59)   \<0.001
   N2                       0.63 (0.55--0.72)   \<0.001                       0.76 (0.66--0.89)                 \<0.001   0.52 (0.41--0.65)   \<0.001
   N3                       1.00 (0.92--1.09)   0.976                         1.21 (1.10--1.33)                 \<0.001   0.67 (0.58--0.77)   \<0.001
  Bone Met                                                                                                                                    
   No                       Ref                 1.0                           Ref                               1.0       Ref                 1.0
   Yes                      0.72 (0.67--0.77)   \<0.001                       0.81 (0.76--0.87)                 \<0.001   0.65 (0.59--0.73)   \<0.001
  Brain Met                                                                                                                                   
   No                       Ref                 1.0                           Ref                               1.0       Ref                 1.0
   Yes                      3.00 (2.69--3.35)   \<0.001                       2.65 (2.37--2.96)                 \<0.001   1.77 (1.51--2.08)   \<0.001
  Liver Met                                                                                                                                   
   No                       Ref                 1.0                           Ref                               1.0       Ref                 1.0
   Yes                      2.06 (1.93--2.21)   \<0.001                       2.15 (2.00--2.32)                 \<0.001   1.21 (1.08--1.36)   0.001
  Lung Met                                                                                                                                    
   No                       Ref                 1.0                           Ref                               1.0       Ref                 1.0
   Yes                      1.75 (1.64--1.87)   \<0.001                       1.80 (1.68--1.93)                 \<0.001   1.20 (1.08--1.33)   0.001
  Surgery                                                                                                                                     
   No surgery               Ref                 1.0                           Ref                               1.0       Ref                 1.0
   PM                       0.41 (0.36--0.47)   \<0.001                       0.38 (0.33--0.45)                 \<0.001   0.69 (0.56--0.85)   \<0.001
   TM                       0.33 (0.28--0.38)   \<0.001                       0.31 (0.26--0.38)                 \<0.001   0.57 (0.44--0.73)   \<0.001
   RM                       0.29 (0.26--0.33)   \<0.001                       0.32 (0.28--0.37)                 \<0.001   0.38 (0.31--0.48)   \<0.001
   Others                   0.38 (0.18--0.79)   0.009                         0.30 (0.12--0.76)                 0.011     0.85 (0.31--2.37)   0.756

SEER -- Surveillance, Epidemiology, and End Result; OR -- odds ratio; CI -- confidence interval; Ref -- reference; NA -- not applicable; UOQ -- upper outer quadrant; LOQ -- lower outer quadrant; LIQ -- lower inner quadrant; UIQ -- upper inner quadrant; CEN -- central portion; NOS -- not otherwise specified; PM -- partial mastectomy; TM -- total mastectomy; RM -- radical mastectomy.

###### 

Multivariate logistic regression for analyzing the risk factors for early death in patients with IV breast cancer.

  Subject characteristics   Total early death   Cancer specific early death   Non-cancer specific early death                                  
  ------------------------- ------------------- ----------------------------- --------------------------------- --------- -------------------- ---------
  Age                                                                                                                                          
  \<50                      Ref                 1.0                           Ref                               1.0       Ref                  1.0
  50--59                    1.59 (1.35--1.89)   \<0.001                       1.51 (1.26--1.80)                 \<0.001   1.52 (1.09--2.13)    0.014
  60--69                    2.22 (1.88--2.63)   \<0.001                       1.84 (1.54--2.20)                 \<0.001   2.5 (1.83--3.44)     \<0.001
  70--79                    3.48 (2.90--4.17)   \<0.001                       2.41 (1.98--2.93)                 \<0.001   4.25 (3.08--5.86)    \<0.001
  ≥80                       7.04 (5.78--8.57)   \<0.001                       3.95 (3.21--4.87)                 \<0.001   7.37 (5.31--10.22)   \<0.001
  Marital status                                                                                                                               
  Married                   Ref                 1.0                           Ref                               1.0       Ref                  1.0
  Unmarried                 1.40 (1.26--1.56)   \<0.001                       1.39 (1.23--1.56)                 \<0.001   1.19 (1--1.42)       0.052
  Race                                                                                                                                         
  White                     Ref                 1.0                           Ref                               1.0       Ref                  1.0
  Black                     1.36 (1.19--1.57)   \<0.001                       1.28 (1.10--1.48)                 0.001     1.34 (1.08--1.67)    0.009
  Others                    0.91 (0.74--1.12)   0.381                         0.94 (0.75--1.17)                 0.570     0.88 (0.61--1.27)    0.505
  Insurance                                                                                                                                    
  Insured                   Ref                 1.0                           Ref                               1.0       Ref                  1.0
  Uninsured                 1.31 (1.00--1.72)   0.048                         1.52 (1.15--2.00)                 0.003     0.61 (0.33--1.11)    0.103
  Subtypes                                                                                                                                     
  Luminal A                 Ref                 1.0                           Ref                               1.0       Ref                  1.0
  Luminal B                 0.78 (0.67--0.91)   0.002                         0.81 (0.68--0.96)                 0.014     0.83 (0.63--1.08)    0.164
  HER2 enriched             1.17 (0.97--1.42)   0.107                         1.11 (0.90--1.36)                 0.318     1.23 (0.9--1.69)     0.193
  Triple Negative           3.76 (3.23--4.37)   \<0.001                       3.06 (2.62--3.57)                 \<0.001   2.09 (1.66--2.62)    \<0.001
  Grade                                                                                                                                        
  Grade I                   Ref                 1.0                           Ref                               1.0       Ref                  1.0
  Grade II                  1.56 (1.25--1.95)   \<0.001                       1.59 (1.22--2.06)                 0.001     1.27 (0.91--1.79)    0.165
  Grade III                 2.22 (1.76--2.79)   \<0.001                       2.29 (1.76--2.99)                 \<0.001   1.42 (1--2.02)       0.053
  Grade IV                  1.44 (0.70--2.93)   0.321                         1.95 (0.94--4.07)                 0.075     0.57 (0.13--2.49)    0.454
  Laterality                                                                                                                                   
  Left-sided                Ref                 1.0                           Ref                               1.0       Ref                  1.0
  Right-sided               0.99 (0.90--1.10)   0.888                         1.00 (0.89--1.12)                 0.998     0.98 (0.83--1.15)    0.768
  One side, NOS             --                  1.000                         --                                1.000     --                   1.000
  Paired sides              2.66 (0.72--9.79)   0.142                         2.45 (0.67--8.94)                 0.176     1.28 (0.15--10.76)   0.821
  Tumor size                                                                                                                                   
  0--2 cm                   Ref                 1.0                           Ref                               1.0       Ref                  1.0
  2--5 cm                   1.05 (0.91--1.22)   0.519                         1.21 (1.02--1.43)                 0.027     0.82 (0.66--1.02)    0.070
  \>5 cm                    1.32 (1.13--1.54)   0.001                         1.69 (1.42--2.01)                 \<0.001   0.67 (0.53--0.86)    0.001
  N stage                                                                                                                                      
  N0                        Ref                 1.0                           Ref                               1.0       Ref                  1.0
  N1                        0.77 (0.67--0.89)   \<0.001                       0.97 (0.84--1.13)                 0.731     0.56 (0.45--0.69)    \<0.001
  N2                        0.82 (0.67--1.01)   0.066                         0.91 (0.72--1.14)                 0.419     0.77 (0.56--1.06)    0.112
  N3                        0.94 (0.81--1.09)   0.395                         1.03 (0.87--1.20)                 0.769     0.84 (0.67--1.05)    0.117
  Bone Met                                                                                                                                     
  No                        Ref                 1.0                           Ref                               1.0       Ref                  1.0
  Yes                       1.11 (0.99--1.24)   0.088                         1.15 (1.02--1.31)                 0.027     0.91 (0.76--1.1)     0.325
  Brain Met                                                                                                                                    
  No                        Ref                 1.0                           Ref                               1.0       Ref                  1.0
  Yes                       3.67 (3.04--4.40)   \<0.001                       2.94 (2.44--3.54)                 \<0.001   2.03 (1.55--2.65)    \<0.001
  Liver Met                                                                                                                                    
  No                        Ref                 1.0                           Ref                               1.0       Ref                  1.0
  Yes                       2.28 (2.03--2.56)   \<0.001                       2.2 (1.95--2.48)                  \<0.001   1.41 (1.17--1.7)     \<0.001
  Lung Met                                                                                                                                     
  No                        Ref                 1.0                           Ref                               1.0       Ref                  1.0
  Yes                       1.30 (1.16--1.45)   \<0.001                       1.36 (1.21--1.53)                 \<0.001   0.96 (0.8--1.15)     0.675
  Surgery                                                                                                                                      
  No surgery                Ref                 1.0                           Ref                               1.0       Ref                  1.0
  PM                        0.46 (0.38--0.56)   \<0.001                       0.44 (0.35--0.54)                 \<0.001   0.76 (0.57--1)       0.049
  TM                        0.42 (0.34--0.51)   \<0.001                       0.41 (0.32--0.52)                 \<0.001   0.71 (0.52--0.98)    0.036
  RM                        0.39 (0.33--0.46)   \<0.001                       0.41 (0.34--0.49)                 \<0.001   0.59 (0.45--0.77)    \<0.001
  Others                    0.75 (0.29--1.94)   0.557                         0.65 (0.22--1.93)                 0.435     1.23 (0.28--5.34)    0.786

SEER -- Surveillance, Epidemiology, and End Result; OR -- odds ratio; CI -- confidence interval; Ref -- reference; NA -- not applicable; UOQ -- upper outer quadrant; LOQ -- lower outer quadrant; LIQ -- lower inner quadrant; UIQ -- upper inner quadrant; CEN -- central portion; NOS -- not otherwise specified; PM -- partial mastectomy; TM -- total mastectomy; RM = radical mastectomy.
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